# Amgen Inc. (AMGN) — Q4-2017 Earnings Results

**Report date:** 2018-02-01 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/AMGN/earnings/Q4-2017

## Post-Earnings Brief

### Headline

Amgen Misses on EPS — Stock Down 0.26%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.89 | N/A | -7.27% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed a cautious outlook while highlighting their focus on future growth. They did not provide specific guidance for the upcoming quarters.

**Key quotes:**

> Management acknowledged the challenging market conditions.

> They emphasized their commitment to innovation and pipeline development.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Amgen's earnings report showed a miss on EPS, which contributed to a slight decline in stock price by 0.26%. Investors may be concerned about the company's performance amidst challenging market conditions. The lack of revenue data and forward guidance adds uncertainty to the outlook.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/AMGN/earnings/Q4-2017_